---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-002529"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2022-04-11T23:59:59+00:00"
generated_at: "2026-06-26T08:22:37.292925+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aptose appoints Philippe Ledru as CCO; CFO Jotin Marango resigns

## Summary
- Philippe Ledru appointed CCO effective April 6, 2022; base salary $410K with up to 40% bonus.
- Dr. Jotin Marango resigns as CFO/CBO to pursue other opportunity; CEO Dr. Rice assumes CAO role.
- Ledru receives a stock option grant for 600,000 common shares under Aptose's 2021 Stock Incentive Plan.
- Ledru previously held senior commercial roles at Merck and Novartis, including oncology pipeline leadership.

## SEC filing metadata
- accession: 0001171843-22-002529
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2022-04-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/f8k_041122.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-002529
- JSON: https://secwatch.observer/filing/0001171843-22-002529.json
- Plain text: https://secwatch.observer/filing/0001171843-22-002529.txt

## Key facts
- Executive change
  Philippe Ledru was appointed as Chief Commercial Officer at Aptose Biosciences Inc..
  - Action: appointed
  - Role: Chief Commercial Officer
  source text: On April 6, 2022, Aptose Biosciences Inc. appointed Mr. Philippe Ledru as its Chief Commercial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm
- Executive change
  Jotin Marango departed as Senior Vice President, Chief Financial Officer and Chief Business Officer at Aptose Biosciences Inc..
  - Action: resigning
  - Role: Senior Vice President, Chief Financial Officer and Chief Business Officer
  source text: Aptose also announced on April 07, 2022 that Dr. Jotin Marango, Senior Vice President, Chief Financial Officer and Chief Business Officer, is resigning to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm
- Executive change
  Dr. Rice changed role as Chief Accounting Officer at Aptose Biosciences Inc..
  - Action: will serve as
  - Role: Chief Accounting Officer
  source text: Dr. Rice will serve as Chief Accounting Officer, and with Ms. Janet Clennett, Vice President of Finance, will assume financial responsibilities until a permanent CFO is announced.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184322002529/0001171843-22-002529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.